OTC · BNYN
Banyan Corp.
$0.00$0.00 (0.0%)
Banyan Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · SCPX · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Scorpius Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Scorpius Holdings, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$54.67. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Scorpius Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in San Antonio, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 27, 2024 | -$0.21+4.55% vs estimate | $4.85M+743.14% vs estimate |
|---|
| Q3 2023 | Nov 20, 2023 | -$1.00-163.16% vs estimate | $723.13K+456.25% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Banyan Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.18$0.00 (0.0%)
Ampio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.55% below the high.
$0.00$0.00 (0.0%)
VMS Rehab Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.02$0.00 (0.0%)
Easy Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
IR Biosciences Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
GlobeStar Therapeutics Corporation: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
GB Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.98% below the high.
$0.00$0.00 (0.0%)
Bioasis Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
